-- Channel Infrastructure(NZE:CHI,ASX:CHI)周一向新西兰和澳大利亚证券交易所提交的文件显示,该公司已确认与新西兰政府达成协议,将在其位于马斯登角能源园区的柴油储存设施新增9300万升的柴油储存容量,相当于新西兰全国约9天的柴油需求量。 根据文件显示,该储存设施预计将于5月31日投入使用,合同有效期至2027年12月31日。预计该设施投入运营后,每月将产生约120万新西兰元的收入。 文件还指出,相关工作已在进行中,包括储罐准备、管道连接以及泵送和仪表系统的安装。 该公司预计将在现有债务能力范围内完成该项目,并预计该项目将在2026年带来约800万新西兰元的额外收入。尽管燃料需求持续存在不确定性,但该公司仍将息税折旧摊销前利润(EBITDA)维持在9500万至1亿新西兰元的预期水平。 该公司在新西兰的股票在周一的交易中上涨了1%。
Related Articles
Fadu Returns to Profit in Q1 as Sales Triple; Shares Jump 14%
Fadu (KOSDAQ:440110) posted first-quarter net income of 10.2 billion won, rebounding from a net loss of 12.1 billion won a year earlier, according to a Monday filing with the Korea Exchange.The South Korean chipmaker's sales revenue surged 210% year over year to 59.5 billion won from 19.2 billion won.Shares of Fadu jumped nearly 14% in recent trade.
ASX Biggest Losers
Here are the 10 ASX-listed companies with the biggest losses on Monday.Wisetech (ASX:WTC): -3%, AU$42.79NexGen Energy (ASX:NXG): -3%, AU$17.26Telix Pharmaceuticals (ASX:TLX): -2%, AU$14.47Cochlear (ASX:COH): -2%, AU$94.76Paladin Energy (ASX:PDN): -2%, AU$12.28Origin Energy (ASX:ORG): -2%, AU$12.44EVT (ASX:EVT): -2%, AU$12.44Tuas (ASX:TUA): -2%, AU$5.97Ramsay Health Care (ASX:RHC): -2%, AU$39.15Southern Cross Gold (ASX:SX2): -2%, AU$11.07
Sun Pharmaceutical to Acquire US-Based Organon in $11.8 Billion Deal
Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) has agreed to acquire US-based Organon & Co in an all-cash deal at an enterprise valuation of $11.8 billion, according to a Monday filing to the Indian stock exchanges.Under the pact, Sun Pharmaceutical will buy all outstanding shares of Organon for $14.00 per share. It plans to fund the acquisition through a combination of available cash resources and committed financing from banks.The acquisition is estimated to boost Sun Pharmaceutical's revenues to $12.4 billion.Organon, which was spun off from Merck in 2021, specializes in women's health and biosimilars and has more than 70 products sold across 140 countries.The Organon buyout is part of Sun Pharmaceutical's strategy "of growing its Innovative Medicines business," according to Sun Pharma's statement.The transaction is subject to customary closing conditions, including receipt of required regulatory approvals andapproval by Organon stockholders.